DBVT News and Press, DBV Technologies S.A. From 08/11/20

Investors had high expectations for Aimmune Therapeutics (NASDAQ: AIMT) at the beginning of the year. Its stock performed well in 2019 -- with its shares surging by more than 30% -- and the biotech was on the verge of getting approval from the U.S. Food and Drug Administration (FDA) for Palf...

Aerpio Pharmaceuticals (NASDAQ: ARPO ) +61%  on announcing a second clinical trial with funding from MTEC. More news on: Aerpio Pharmaceuticals, Inc., Whiting Petroleum Corporation, Hepion Pharmaceuticals, Inc., Stocks on the move, , Read more ...

Gainers:  Alterity Therapeutics (NASDAQ: ATHE ) +210% . More news on: Alterity Therapeutics Limited, SilverSun Technologies, Inc., Universal Security Instruments, Inc., Stocks on the move, , Read more ...

DBV Technologies  (NASDAQ: DBVT )   slumps 30%  premarket in reaction to its announcement that it received a Complete Response Letter (CRL) from the FDA regarding its BLA for investigational Viaskin Peanut (DBV712), a non-invasive, once-daily epicutaneous patch to treat pean...

Montrouge, France, August 4, 2020 DBV Technologies Receives Complete Response Letter from FDA for Viaskin Peanut BLA in Children Ages 4-11 Years DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced ...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Volatility watch: Short interest is in an uptrend for Vale (NYSE: VALE ) , Nokia (NYSE: NOK ) , United Airlines (NASDAQ: UAL ) , Micron Technology (NASDAQ: MU ) and Denbury Resources (NYSE: DNR ) , while GameStop (NYSE: GME ) , National Beverage (NASDAQ: FIZZ ) and Dillard's (NYSE:...

Montrouge, France, July 31, 2020 DBV Technologies Reports First Half 2020 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today reported first half 2020 financial results. The interim ...

Monthly information regarding the total number of voting rights and  total number of shares of the Company as of June 30, 2020 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Cod...

DBV Technologies Reports Positive Extension Study Results DBV Technologies (DBVT) reported positive results from its open label extension of the Phase 3 study. The data showed that the participants underwent sustained clinical benefit with an extra two years of treatment with Viaskin Pea...